Results 1-3 of 3 (Search time: 0.002 seconds).
Issue Date | Title | Author(s) | Relation | scopus | WOS | Fulltext/Archive link | |
---|---|---|---|---|---|---|---|
1 | 2019 | Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. | Han, Y; Chen, MK; Wang, HL; Hsu, JL; Li, CW ; Chu, YY; Liu, CX; Nie, L; Chan, LC; Yam, C; Wang, SC; He, GJ; Hortobagyi, GN; Tan, XD; Hung, MC | American journal of cancer research 9(3), 608-618 | |||
2 | 2017 | PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. | Jiao, S; Xia, W; Yamaguchi, H; Wei, Y; Chen, MK; Hsu, JM; Hsu, JL; Yu, WH; Du, Y; Lee, HH; Li, CW ; Chou, CK; Lim, SO; Chang, SS; Litton, J; Arun, B; Hortobagyi, GN; Hung, MC | Clinical cancer research : an official journal of the American Association for Cancer Research 23(14), 3711-3720 | |||
3 | 2014 | Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. | Hsu, YH; Yao, J; Chan, LC; Wu, TJ; Hsu, JL; Fang, YF; Wei, Y; Wu, Y; Huang, WC; Liu, CL; Chang, YC; Wang, MY; Li, CW ; Shen, J; Chen, MK; Sahin, AA; Sood, A; Mills, GB; Yu, D; Hortobagyi, GN; Hung, MC | Cancer research 74(17), 4822-4835 |